Evidence map›Paper›PMID 31865534›Full record

ArticleWorld journal of urology2020

Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau).

Lukas Werner Prause, Lukas Manka, Christopher Millan, Elena Lang, Stephen F Wyler, Rainer Grobholz, Angelika Hammerer-Lercher, Tullio Sulser, Franz Recker, Maciej Kwiatkowski and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Lukas Werner PrauseDepartment of Urology, University Hospital Zurich, Zurich, Switzerland. lukas.prause@gmail.com.ORCID http://orcid.org/0000-0002-1563-3543
Lukas MankaDepartment of Urology, Academic Hospital Braunschweig, Braunschweig, Germany. l.manka@klinikum-braunschweig.de.
Christopher MillanDepartment of Urology, University Hospital Zurich, Zurich, Switzerland.
Elena LangDepartment of Urology, University Hospital Zurich, Zurich, Switzerland.
Stephen F WylerDepartment of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
Rainer GrobholzInstitute of Pathology, Cantonal Hospital Aarau, Aarau, Switzerland.
Angelika Hammerer-LercherDepartment of Laboratory Medicine, Cantonal Hospital Aarau, Aarau, Switzerland.
Tullio SulserDepartment of Urology, University Hospital Zurich, Zurich, Switzerland.
Franz ReckerDepartment of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
Maciej KwiatkowskiDepartment of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
Daniel EberliDepartment of Urology, University Hospital Zurich, Zurich, Switzerland.
University Hospital of Zurich · CHKantonsspital Aarau · CHUniversity of Basel · CHKlinikum Braunschweig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo analyze the influence of aspirin (ASA) intake on PSA values and prostate cancer (PCa) development in a prospective screening study cohort.

methods4314 men from the Swiss section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) were included. A transrectal prostate biopsy was performed in men with a PSA level ≥ 3 ng/ml. Mortality data were obtained through registry linkages. PCa incidence and grade, total PSA, free-to-total PSA and overall survival were compared between ASA users and non-users.

resultsMedian follow-up time was 9.6 years. In 789 men (18.3%) using aspirin [ASA +], the overall PCa incidence was significantly lower (6.8% vs. 9.6%, p = 0.015), but the multivariate Cox regression analysis showed no significant decrease in risk of PCa diagnosis (HR 0.84, p = 0.297). Total PSA values were significantly lower in ASA users for both baseline (1.6 vs. 1.8 ng/ml, p = 0.007) and follow-up visits (1.75 vs. 2.1 ng/ml, p < 0.001). Multivariate Cox regression analysis predicted significantly higher overall mortality risk among ASA users (HR 1.46, p = 0.009).

conclusionsIn our study population, PCa incidence was significantly reduced among patients on aspirin. While we did not observe a statistically significant PCa risk reduction during the follow-up period, we found lower PSA values among ASA users compared to non-users, with a more distinct difference after 4 years of ASA intake, suggesting a cumulative effect and a potential protective association between regular ASA intake and PCa development. As for clinical practice, lowering PSA cutoff values by 0.4 ng/ml could be considered in long-term ASA users to avoid a potential bias towards delayed PCa detection.

Indexed as

Early Detection of CancerAgedAspirinHumansIncidenceMaleMiddle AgedProspective StudiesProstate-Specific AntigenProstatic NeoplasmsSurvival RateSwitzerlandAspirinProstate-Specific AntigenAcetylsalicylic acidAspirinChemopreventionProstate cancerProstate-specific antigenScreening

Identifiers

PMID31865534
OpenAlexW2995580291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.